Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGylated G-CSF prophylaxis for chemotherapy-induced neutropenia in solid tumors
ChiCTR1800019675Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN), sponsored by Tongji Hospital. Primary endpoint: Incidence of grade III/IV ANC reduction in each chemotherapy cycle. Started Nov 2018; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on ChiCTR1800019675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019675.